BH3 mimetics antagonizing restricted prosurvival Bcl-2 proteins represent another class of selective immune modulatory drugs

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 24, 2010, Pages 10967-10971

  Carrington, Emma M ^a   Vikstrom, Ingela B ^a   Light, Amanda ^a   Sutherland, Robyn M ^a   Londrigan, Sarah L ^a,b   Mason, Kylie D ^a   Huang, David C S ^a   Lew, Andrew M ^a   Tarlinton, David M ^a  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Apoptosis; Immunity; Memory; Transplantation

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; 4 HYDROXY 3 NITROPHENYL ACETYL KEYHOLE LIMPET HEMOCYANIN; BCL2 RELATED PROTEIN A1; BH3 PROTEIN; IMMUNOMODULATING AGENT; PROTEIN BCL 2; PROTEIN BCL W; PROTEIN BCL XL; PROTEIN MCL 1; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; B LYMPHOCYTE; BONE MARROW CELL; CELL KILLING; CELL SUBPOPULATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; DIABETES MELLITUS; DRUG MEGADOSE; GERMINAL CENTER; GRAFT REJECTION; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; LYMPH NODE; LYMPHOCYTE; MEMORY CELL; MOUSE; NONHUMAN; PANCREAS TRANSPLANTATION; PLASMA CELL; PRIORITY JOURNAL; PROTEIN DOMAIN; SURVIVAL TIME; T LYMPHOCYTE;

ANIMALS; APOPTOSIS; B-LYMPHOCYTES; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; BIPHENYL COMPOUNDS; GRAFT REJECTION; IMMUNITY, HUMORAL; IMMUNOLOGIC FACTORS; ISLETS OF LANGERHANS TRANSPLANTATION; LEUKOCYTES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED CBA; MICE, INBRED NOD; MICE, KNOCKOUT; NITROPHENOLS; PEPTIDE FRAGMENTS; PIPERAZINES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; SULFONAMIDES; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, CYTOTOXIC; TRANSPLANTATION, HOMOLOGOUS;

EID: 77954649027     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1005256107     Document Type: Article

References (31)

1. Augustine JJ, Bodziak KA, Hricik DE (2007) Use of sirolimus in solid organ transplantation. Drugs 67:369-391. (Pubitemid 46425551)
2. Knoll G (2008) Trends in kidney transplantation over the past decade. Drugs 68(Suppl 1):3-10.
3. Strasser A (2005) The role of BH3-only proteins in the immune system. Nat Rev Immunol 5:189-200. (Pubitemid 40364821)
4. Green DR (2005) Apoptotic pathways: Ten minutes to dead. Cell 121:671-674.
5. Newmeyer DD, Ferguson-Miller S (2003) Mitochondria: releasing power for life and unleashing the machineries of death. Cell 112:481-490.
6. Oltersdorf T, et al. (2005) An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435:677-681.
7. Konopleva M, et al. (2006) Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 10:375-388.
8. van Delft MF, et al. (2006) The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 10:389-399.
9. Huntington ND, et al. (2007) Interleukin 15-mediated survival of natural killer cells is determined by interactions among Bim, Noxa and Mcl-1. Nat Immunol 8:856-863.
10. Moulding DA, Quayle JA, Hart CA, Edwards SW(1998)Mcl-1 expression in human neutrophils: Regulation by cytokines and correlation with cell survival. Blood 92:2495-2502.
11. Tarlinton D, Radbruch A, Hiepe F, Dörner T (2008) Plasma cell differentiation and survival. Curr Opin Immunol 20:162-169.
12. Cragg MS, et al. (2008) Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic. J Clin Invest 118:3651-3659.
13. Tse C, et al. (2008) ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 68:3421-3428.
14. Kahan BD (1999) Cyclosporine: A revolution in transplantation. Transplant Proc 31(1-2A):14S-15S.
15. Ptachcinski RJ, Burckart GJ, Venkataramanan R (1985) Cyclosporine. Drug Intell Clin Pharm 19:90-100.
16. Helderman JH, Goral S (2002) Gastrointestinal complications of transplant immunosuppression. J Am Soc Nephrol 13:277-287.
17. Shapiro AM, et al. (2005) Strategic opportunities in clinical islet transplantation. Transplantation 79:1304-1307. (Pubitemid 40734790)
18. Ekberg H (2008) Calcineurin inhibitor sparing in renal transplantation. Transplantation 86:761-767.
19. Kobayash H, et al. (2000) Immunohistochemical analysis of apoptosis-related proteins in human embryonic and fetal pancreatic tissues. Int J Pancreatol 27:113-122.
20. Pérarnau B, et al. (1999) Single H2Kb, H2Db and double H2KbDb knockout mice: Peripheral CD8+ T cell repertoire and anti-lymphocytic choriomeningitis virus cytolytic responses. Eur J Immunol 29:1243-1252.
21. Sutherland RM, et al. (2004) Bcl-2 protection of islet allografts is unmasked by costimulation blockade. Transplantation 77:1610-1613.
22. Knudson CM, Tung KS, Tourtellotte WG, Brown GA, Korsmeyer SJ (1995) Bax-deficient mice with lymphoid hyperplasia and male germ cell death. Science 270:96-99.
23. Lindsten T, et al. (2000) The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues. Mol Cell 6:1389-1399.
24. Rathmell JC, Lindsten T, Zong WX, Cinalli RM, Thompson CB (2002) Deficiency in Bak and Bax perturbs thymic selection and lymphoid homeostasis. Nat Immunol 3: 932-939. (Pubitemid 35154006)
25. Mason KD, et al. (2007) Programmed anuclear cell death delimits platelet life span. Cell 128:1173-1186.
26. Smith KG, Light A, Nossal GJ, Tarlinton DM (1997) The extent of affinity maturation differs between the memory and antibody-forming cell compartments in the primary immune response. EMBO J 16:2996-3006. (Pubitemid 27234939)
27. Vremec D, Pooley J, Hochrein H, Wu L, Shortman K (2000) CD4 and CD8 expression by dendritic cell subtypes in mouse thymus and spleen. J Immunol 164:2978-2986. (Pubitemid 30148956)
28. Ridderstad A, Tarlinton DM (1998) Kinetics of establishing the memory B cell population as revealed by CD38 expression. J Immunol 160:4688-4695. (Pubitemid 28215301)
29. Lalor PA, Nossal GJ, Sanderson RD, McHeyzer-Williams MG (1992) Functional and molecular characterization of single, (4-hydroxy-3-nitrophenyl)acetyl (NP)-specific, IgG1+ B cells from antibody-secreting and memory B cell pathways in the C57BL/6 immune response to NP. Eur J Immunol 22:3001-3011.
30. Oehen S, Brduscha-Riem K (1998) Differentiation of naive CTL to effector and memory CTL: correlation of effector function with phenotype and cell division. J Immunol 161:5338-5346. (Pubitemid 28519094)
31. Liu M, Shapiro ME (1995) A new method for isolation of murine islets with markedly improved yields. Transplant Proc 27:3208-3210. (Pubitemid 26016142)